{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:42:06Z","timestamp":1754152926568,"version":"3.41.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Low blood pressure at acute ischemic stroke onset is associated with both short- and long-term adverse outcomes. Studies have shown that YQFM (YiQiFuMai lyophilized injection) can ameliorate neurological deficits in ischemic stroke.However, all of these studies are all small-sample clinical observations lacking rigorous study design for AIS with inappropriate blood pressure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To describe the design of the YQFM aimed at reducing the disability rate in AIS patients with inappropriate blood pressure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This trial is a prospective, multicenter, randomized, double-blind, placebo-controlled, superiority trial aimed at evaluating the efficacy and safety of YQFM in reducing the disability rate in patients with acute hypoperfusion stroke within 90 days. We will recruit 480 patients with AIS within 48\u00a0h of symptom onset from 24 hospitals, who have large atherosclerosis, systolic pressure\u2009\u2264\u2009155 mmHg, and an NIHSS score of 4\u201318. Eligible patients will be randomly assigned to receive either YQFM or 0.9% NaCl injection once daily for 10 days and will be followed up until the 90th day after stroke onset.The primary outcome will be the proportion of patients with mRS\u2009\u2264\u20092 at 90 days after patient recruitment. Secondary outcomes will include the proportion of early neurological deterioration at 7 days, patient self-reported outcomes and the syndrome score at 10 days, MMSE scale and BI scale at 90 days.During the trial, adverse events will be recorded. These data will be analyzed according to the predetermined statistical analysis plan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study is the first randomized controlled double-blind trial to evaluate the efficacy and safety of YQFM in patients with AIS. This trial will provide evidence-based data for YQFM application in AIS with inappropriate blood pressure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>ChiCTR2300074125 was registered on 31 July, 2023. For more information, please visit Clinical Trials.gov at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.chictr.org.cn\/showproj.html?Proj=200686\" ext-link-type=\"uri\">https:\/\/www.chictr.org.cn\/showproj.html?Proj=200686<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12906-025-05036-0","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:07:50Z","timestamp":1753189670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of YQFM (YiQiFuMai lyophilized injection) on acute ischemic stroke (FAST): rationale and design for a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Yingzhi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyou","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiu","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boxuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaosheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kegang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"10","key":"5036_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","volume":"23","author":"GBD 2021 Stroke Risk Factor Collaborators","year":"2024","unstructured":"GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and National burden of stroke and its risk factors, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet Neurol. 2024;23(10):973\u20131003. https:\/\/doi.org\/10.1016\/S1474-4422(24)00369-7. PMID: 39304265.","journal-title":"Lancet Neurol"},{"key":"5036_CR2","unstructured":"Wang Y, Li Z, Gu H, Zhai Q, Jiang Y, Zhao ZQ, Wang X, Yang Y, Jiang X, Zhou Y, Zhao Q, Wang X, Yang Y, Wang X, Meng C, Li X, Liu H, Dong Q, Wang DJ, Wu J, Xu A, Wang W, Ma X, Zhao J. China stroke report 2020 (Chinese version). Chin J Stroke. 2022;17(5):433\u201347"},{"issue":"11","key":"5036_CR3","first-page":"78393","volume":"20","author":"Report on Stroke Prevention and Treatment in China Writing Group","year":"2023","unstructured":"Report on Stroke Prevention and Treatment in China Writing Group. Summary of China stroke prevention report 2021. Chin J Cerebrovasc Dis. 2023;20(11):78393.","journal-title":"Chin J Cerebrovasc Dis"},{"issue":"8","key":"5036_CR4","doi-asserted-by":"publisher","first-page":"e2120745","DOI":"10.1001\/jamanetworkopen.2021.20745","volume":"4","author":"HQ Gu","year":"2021","unstructured":"Gu HQ, Yang X, Wang CJ, Zhao XQ, Wang YL, Liu LP, Meng X, Jiang Y, Li H, Liu C, Wangqin R, Fonarow GC, Schwamm LH, Xian Y, Li ZX, Wang YJ. Clinical characteristics, management, and In-Hospital outcomes in patients with stroke or transient ischemic attack in China. JAMA Netw Open. 2021;4(8):e2120745. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20745.","journal-title":"JAMA Netw Open"},{"issue":"37","key":"5036_CR5","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1093\/eurheartj\/ehx330","volume":"38","author":"S Bangalore","year":"2017","unstructured":"Bangalore S, Schwamm L, Smith EE, Hellkamp AS, Suter RE, Xian Y, Schulte PJ, Fonarow GC, Bhatt DL. Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. Eur Heart J. 2017;38(37):2827\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehx330.","journal-title":"Eur Heart J"},{"key":"5036_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/svn-2016-000020","volume":"1","author":"JP Appleton","year":"2016","unstructured":"Appleton JP, Sprigg N, Bath PM. Blood pressure management in acute stroke. Stroke Vascul Neurol. 2016;1:72\u201382. https:\/\/doi.org\/10.1136\/svn-2016-000020.","journal-title":"Stroke Vascul Neurol"},{"issue":"3","key":"5036_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annemergmed","volume":"64","author":"J Miller","year":"2014","unstructured":"Miller J, Kinni H, Lewandowski C, Nowak R, Levy P. Management of hypertension in stroke. Ann Emerg Med. 2014;64(3):248\u201355. https:\/\/doi.org\/10.1016\/j.annemergmed.","journal-title":"Ann Emerg Med"},{"issue":"7","key":"5036_CR8","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1161\/STROKEAHA.109.548602","volume":"40","author":"N Ahmed","year":"2009","unstructured":"Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from safe implementation of thrombolysis in stroke-International stroke thrombolysis register (SITS-ISTR). Stroke. 2009;40(7):2442\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.109.548602.","journal-title":"Stroke"},{"issue":"9767","key":"5036_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(11)60104-9","volume":"377","author":"EC Sandset","year":"2011","unstructured":"Sandset EC, Bath PM, Boysen G, Jatuzis D, K\u00f5rv J, L\u00fcders S, Murray GD, Richter PS, Roine RO, Ter\u00e9nt A, Thijs V, Berge E. The angiotensin-receptor blocker Candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377(9767):741\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(11)60104-9.","journal-title":"Lancet"},{"issue":"9","key":"5036_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1474-4422(19)30196-6","volume":"18","author":"TJ Moullaali","year":"2019","unstructured":"Moullaali TJ, Wang X, Martin RH, Shipes VB, Robinson TG, Chalmers J, Suarez JI, Qureshi AI, Palesch YY. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a Preplanned pooled analysis of individual participant data. Lancet Neurol. 2019;18(9):857\u201364. https:\/\/doi.org\/10.1016\/S1474-4422(19)30196-6.","journal-title":"Lancet Neurol"},{"issue":"10174","key":"5036_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0140-6736(19)30038-8","volume":"393","author":"CS Anderson","year":"2019","unstructured":"Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, Li Q, Billot L, Delcourt C, Bath PM, Broderick JP, Demchuk AM, Donnan GA, Durham AC, Lavados PM, Lee TH, Levi C, Martins SO, Olavarria VV, Pandian JD. ENCHANTED investigators and coordinators (2019). Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019;393(10174):877\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(19)30038-8.","journal-title":"Lancet"},{"issue":"5","key":"5036_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1161\/01.str.0000014509.11540.66","volume":"33","author":"J Leonardi-Bee","year":"2002","unstructured":"Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA, IST Collaborative Group. Blood pressure and clinical outcomes in the international stroke trial. Stroke. 2002;33(5):1315\u201320. https:\/\/doi.org\/10.1161\/01.str.0000014509.11540.66.","journal-title":"Stroke"},{"issue":"2","key":"5036_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/01.STR.0000109769.22917.B0","volume":"35","author":"J Castillo","year":"2004","unstructured":"Castillo J, Leira R, Garc\u00eda MM, Serena J, Blanco M, D\u00e1valos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35(2):520\u20136. https:\/\/doi.org\/10.1161\/01.STR.0000109769.22917.B0.","journal-title":"Stroke"},{"issue":"6","key":"5036_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1097\/01.hjh.0000170385.76826.4a","volume":"23","author":"K Okumura","year":"2005","unstructured":"Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens. 2005;23(6):1217\u201323. https:\/\/doi.org\/10.1097\/01.hjh.0000170385.76826.4a.","journal-title":"J Hypertens"},{"issue":"8","key":"5036_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1212\/01.wnl.0000180939.24845.22","volume":"65","author":"LG Stead","year":"2005","unstructured":"Stead LG, Gilmore RM, Decker WW, Weaver AL, Brown RD Jr. Initial emergency department blood pressure as predictor of survival after acute ischemic stroke. Neurology. 2005;65(8):1179\u201383. https:\/\/doi.org\/10.1212\/01.wnl.0000180939.24845.22.","journal-title":"Neurology"},{"issue":"2","key":"5036_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2796.2003.01291.x","volume":"255","author":"KN Vemmos","year":"2004","unstructured":"Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004;255(2):257\u201365. https:\/\/doi.org\/10.1046\/j.1365-2796.2003.01291.x.","journal-title":"J Intern Med"},{"issue":"3","key":"5036_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1161\/STROKEAHA.120.033195","volume":"53","author":"HJ Aparicio","year":"2022","unstructured":"Aparicio HJ, Tarko LM, Gagnon D, Costa L, Galloway A, Demissie S, Djousse L, Seshadri S, Cho K, Wilson PWF. Low blood pressure, comorbidities, and ischemic stroke mortality in US veterans. Stroke. 2022;53(3):886\u201394. https:\/\/doi.org\/10.1161\/STROKEAHA.120.033195.","journal-title":"Stroke"},{"issue":"2","key":"5036_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/HJH.0000000000002649","volume":"39","author":"M Ouyang","year":"2021","unstructured":"Ouyang M, Mu\u00f1oz-Venturelli P, Billot L, Wang X, Song L, Arima H, Lavados PM, Hackett ML, Olavarr\u00eda VV, Brunser A, Middleton S, Pontes-Neto OM, Lee TH, Watkins CL, Robinson T, Anderson CS. Low blood pressure and adverse outcomes in acute stroke: headpost study explanations. J Hypertens. 2021;39(2):273\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000002649.","journal-title":"J Hypertens"},{"issue":"6","key":"5036_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/01.str.12.6.723","volume":"12","author":"J Astrup","year":"1981","unstructured":"Astrup J, Siesj\u00f6 BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke. 1981;12(6):723\u20135. https:\/\/doi.org\/10.1161\/01.str.12.6.723.","journal-title":"Stroke"},{"issue":"9","key":"5036_CR20","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1161\/01.STR.0000236024.68020.3a","volume":"37","author":"RF Gottesman","year":"2006","unstructured":"Gottesman RF, Sherman PM, Grega MA, Yousem DM, Borowicz LM Jr, Selnes OA, Baumgartner WA, McKhann G. M.Watershed strokes after cardiac surgery: diagnosis, etiology, and outcome. Stroke. 2006;37(9):2306\u201311. https:\/\/doi.org\/10.1161\/01.STR.0000236024.68020.3a.","journal-title":"Stroke"},{"issue":"3","key":"5036_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/01.STR.0000155727.82242.e1","volume":"36","author":"I Momjian-Mayor","year":"2005","unstructured":"Momjian-Mayor I, Baron JC. The pathophysiology of watershed infarction in internal carotid artery disease: review of cerebral perfusion studies. Stroke. 2005;36(3):567\u201377. https:\/\/doi.org\/10.1161\/01.STR.0000155727.82242.e1.","journal-title":"Stroke"},{"issue":"1","key":"5036_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1590\/s0004-282x2004000100007","volume":"62","author":"TR Noce","year":"2004","unstructured":"Noce TR, F\u00e1bio SR, Siqueira Neto JI, dos Santos AC, Funayama CA. Cerebral infarct in children aged zero to fifteen years. Arq Neuropsiquiatr. 2004;62(1):38\u201343. https:\/\/doi.org\/10.1590\/s0004-282x2004000100007.","journal-title":"Arq Neuropsiquiatr"},{"issue":"6","key":"5036_CR23","doi-asserted-by":"publisher","first-page":"56567","DOI":"10.3969\/j.issn.1008691.2016.06.002","volume":"23","author":"C Yin","year":"2016","unstructured":"Yin C, Wang Y, Lu P. Effect of buterphthalin combined with Ukline on the area of ischemic hypoperfusion and clinical efficacy evaluation in patients with acute cerebral infarction [J]. Chin Emerg J Integr Traditional Chin Western Med. 2016;23(6):56567. https:\/\/doi.org\/10.3969\/j.issn.1008691.2016.06.002.","journal-title":"Chin Emerg J Integr Traditional Chin Western Med"},{"issue":"16","key":"5036_CR24","doi-asserted-by":"publisher","first-page":"2240243","DOI":"10.19435\/j.1672721.2021.16.009","volume":"25","author":"Y Lin","year":"2021","unstructured":"Lin Y, Li X, Chen M. Effect of Raw pulse injection adjuvant therapy on cerebral hemodynamics in patients with hypoperfusion \/ embolus clearance ability decreased cerebral infarction [J]. Grassroots Med Forum. 2021;25(16):2240243. https:\/\/doi.org\/10.19435\/j.1672721.2021.16.009.","journal-title":"Grassroots Med Forum"},{"issue":"12","key":"5036_CR25","first-page":"23637","volume":"9","author":"YF Wang","year":"2014","unstructured":"Wang YF, Wang JL, Lin JJ. Comparison of the efficacy of shengmai injection and shenmai injection for acute hypoperfusion cerebral infarction [J]. Chin Med Econ. 2014;9(12):23637.","journal-title":"Chin Med Econ"},{"issue":"5","key":"5036_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/molecules21050640","volume":"21","author":"C Liu","year":"2016","unstructured":"Liu C, Ju A, Zhou D, Li D, Kou J, Yu B, Qi J. Simultaneous qualitative and quantitative analysis of multiple chemical constituents in YiQiFuMai injection by Ultra-Fast liquid chromatography coupled with ion trap Time-of-Flight mass spectrometry. Molecules. 2016;21(5):640. https:\/\/doi.org\/10.3390\/molecules21050640.","journal-title":"Molecules"},{"issue":"48","key":"5036_CR27","doi-asserted-by":"publisher","first-page":"4548550","DOI":"10.6039\/j.issn.1001408.2014.48.12","volume":"25","author":"Q Qiao","year":"2014","unstructured":"Qiao Q, An Zh P. Comparison of the efficacy of Yiyifumai injection and Ginkgo biloba extract injection in the treatment of acute cerebral infarction. Pharm China. 2014;25(48):4548550. https:\/\/doi.org\/10.6039\/j.issn.1001408.2014.48.12.","journal-title":"Pharm China"},{"key":"5036_CR28","doi-asserted-by":"publisher","unstructured":"Chen XD. Efficacy and mechanism of action in treating acute cerebral infarction in 41 cases. World Traditional Chinese Medicine,2010,5 (05): 31416.https:\/\/doi.org\/10.3969\/j.issn.1673202. 2010.05.006.","DOI":"10.3969\/j.issn.1673202"},{"issue":"3","key":"5036_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, Hr\u00f3bjartsson A, Mann H, Dickersin K, Berlin JA, Dor\u00e9 CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"key":"5036_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3760\/cma.j.issn.1006876.2018.09.004","volume":"51","author":"Chinese Society of Neurology","year":"2018","unstructured":"Chinese Society of Neurology. Chinese stroke society.chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. Zhonghua Shen Jing Ke Za Zhi. 2018;51:666\u201382. https:\/\/doi.org\/10.3760\/cma.j.issn.1006876.2018.09.004.","journal-title":"Zhonghua Shen Jing Ke Za Zhi"},{"key":"5036_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/DDDT.S96818","volume":"10","author":"G Cao","year":"2016","unstructured":"Cao G, Ye X, Xu Y, Yin M, Chen H, Kou J, Yu B. YiQiFuMai powder injection ameliorates blood-brain barrier dysfunction and brain edema after focal cerebral ischemia-reperfusion injury in mice. Drug Des Devel Ther. 2016;10:315\u201325. https:\/\/doi.org\/10.2147\/DDDT.S96818.","journal-title":"Drug Des Devel Ther"},{"key":"5036_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jep.2016.02.028","volume":"183","author":"GS Cao","year":"2016","unstructured":"Cao GS, Chen HL, Zhang YY, Li F, Liu CH, Xiang X, Qi J, Chai CZ, Kou JP, Yu BY. YiQiFuMai powder injection ameliorates the oxygen-glucose deprivation-induced brain microvascular endothelial barrier dysfunction associated with the NF-\u03baB and ROCK1\/MLC signaling pathways. J Ethnopharmacol. 2016;183:18\u201328. https:\/\/doi.org\/10.1016\/j.jep.2016.02.028.","journal-title":"J Ethnopharmacol"},{"key":"5036_CR33","doi-asserted-by":"publisher","first-page":"153882","DOI":"10.1016\/j.phymed.2021.153882","volume":"95","author":"L Su","year":"2022","unstructured":"Su L, Liu Y, Ma H, Zheng F, Daia Y, Wang T, Wang G, Li F, Zhang Y, Yu B, Gong S, Kou J. YiQiFuMai lyophilized injection attenuates cerebral ischemic injury with Inhibition of neuronal autophagy through intervention in the NMMHC IIA-actin-ATG9A interaction. Phytomedicine. 2022;95:153882. https:\/\/doi.org\/10.1016\/j.phymed.2021.153882.","journal-title":"Phytomedicine"},{"issue":"3","key":"5036_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","volume":"38","author":"JL Banks","year":"2007","unstructured":"Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38(3):1091\u20136. https:\/\/doi.org\/10.1161\/01.STR.0000258355.23810.c6.","journal-title":"Stroke"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05036-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:07:58Z","timestamp":1753189678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-05036-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5036"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05036-0","relation":{},"ISSN":["2662-7671"],"issn-type":[{"type":"electronic","value":"2662-7671"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial protocol was reviewed and approved by the Ethics Committee of Dongzhimen Hospital, Beijing University of Chinese Medicine (2023DZMEC492). This clinical trial protocol complies with the relevant provisions of the Declaration of Helsinki and Tokyo for the protection of subjects.Subjects participating in this study will provide written informed consent. During the clinical trial, the personal information of the subject cannot appear in any clinical information.The subject name must be replaced by the number. This trial has purchased insurance for each patient, and if a major serious adverse event occurs during the trial, the insurance company will compensate the patient accordingly.Any modifications to the protocol which may impact on the conduct of the study, patients\u2019potential benefit or safety will require a formal amendment to the protocol. Such amendment will be agreed upon by sponsor and principal investigator, and approved by the Ethics Committee prior to implementation.Version control will use protocol identifiers and dates, as well as a list of amendments, to help track the history of amendments and identify the most recent protocol version.To ensure the impartiality and independence of the project, the Principal Investigator signed the statement of conflict of interest.The informed documents were drafted and distributed to the researchers at medical centers, and the informed documents were modified to meet the local ethical requirements.The participants provided their written informed consent to participate in this trial.The first participant in the FAST trial was randomized on January 9, 2024. By the time of this submission, a total of 298 patients have been enrolled. The full enrollment is expected to conclude by August 2025, with follow-up visits anticipated to be finished by November 2025. The primary results will be disclosed by February 2026.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}